Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. - Wikidata - awgldk - TriplyDB

Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.

Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.

http://www.wikidata.org/entity/Q34208293

about

Immunotherapy for cancer in the central nervous system: Current and future directions Sui generis: gene therapy and delivery systems for the treatment of glioblastoma Immunotherapy for primary brain tumors: no longer a matter of privilege An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma Progress and problems with the use of suicide genes for targeted cancer therapy Current clinical trials testing the combination of immunotherapy with radiotherapy.Stem cells' guided gene therapy of cancer: New frontier in personalized and targeted therapy.Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses.Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors.Adenoviral vector-mediated gene therapy for gliomas: coming of age.Current status of gene therapy for brain tumors.Prognostic utility of gene therapy with herpes simplex virus thymidine kinase for patients with high-grade malignant gliomas: a systematic review and meta analysis.Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model.Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model The art of gene therapy for glioma: a review of the challenging road to the bedside Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice.Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer.Switching a replication-defective adenoviral vector into a replication-competent, oncolytic adenovirus.Glioma virus therapies between bench and bedside.Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models.Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma The spectrum of vaccine therapies for patients with glioblastoma multiforme Current status of immunotherapy and gene therapy for high-grade gliomas.Progress in gene therapy for neurological disorders.Devices for cell transplantation into the central nervous system: Design considerations and emerging technologies.Clinical trials of viral therapy for malignant gliomas.Gene-directed enzyme prodrug therapy.Stem cell in alternative treatments for brain tumors: potential for gene delivery.Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization.Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response.Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma Immunological effects of chemotherapy and radiotherapy against brain tumors.Enzyme/Prodrug Systems for Cancer Gene Therapy.Immune and viral therapies for malignant primary brain tumors.Integration of adenovirus thymidine kinase suicide-gene therapy with surgery and radiation therapy for malignant glioma.Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma.A slow-release fibrin matrix increases adeno-associated virus transduction of wound repair cells in vivo.Technical Pitfalls of Signal Truncation in Perfusion MRI of Glioblastoma.Oncolytic virotherapy for gliomas: steps toward the future.

P2860

Q26750765-66E009A8-A573-45F6-BD5E-955AD520737F Q26850467-54424C0B-D4F1-450D-B02C-D90982D34969 Q27002510-4326B727-8937-4259-9E44-FE6A2F5F8D3F Q27024830-C095ECE6-03E4-4618-B15F-B72D4CB556B4 Q28262370-D8EA5A11-34A1-49EF-AAB5-AF8F3A892602 Q30356447-0330E86C-3ADE-4E7B-8E98-026F0D3E29D7 Q33653485-A1D583E5-69B2-4BF2-883A-4959C8B577FC Q33923950-C6352B34-95DF-45C4-9493-FEF6DD1C6A5B Q33950709-32A565A0-EC04-4352-9EA3-2B10AA06B142 Q34022048-FE68B6B0-F19B-4F70-B25B-D3D248384B72 Q34318157-F4E213E2-85B3-45AC-BD36-B42FBD0AB395 Q35155376-B527A9D5-14B4-4758-BD91-C6C3DED2C014 Q35973436-2A8629C3-DBCA-41B8-AB24-1B74FFAA2BF9 Q36345439-A72C7B07-1BBC-4D99-86A7-38DB042C93B5 Q36527593-96F990E5-1577-4C17-A475-8FD2AC6809FE Q36634430-E671914B-D247-40E2-80E8-B8BC97F4586C Q36811505-86046C24-C0AA-48E8-817A-741A5BE8A998 Q37347492-76434672-FE75-4537-AFD8-19185445EA2E Q37547783-2A4E93D2-F223-4C27-8904-CF56DFF88613 Q37580510-C0A8E658-77EE-4CB8-A633-8ABA90A117EA Q37647868-D8AC63F3-831F-4F80-BC04-84D37520E424 Q37730116-C6A6BBF7-B563-46DC-B3E6-FF89CB112CB5 Q38035788-CDC018C5-7AE1-4A2D-826E-04392A0D7845 Q38072814-095DB777-C39F-4DE0-9D9D-485709DE8232 Q38100997-DA0F37FB-A2CD-45D3-8178-4B4A3B2EA5F6 Q38105080-39145283-07C0-4C39-9E93-7BB98AB2C213 Q38153777-137F799D-EFCC-4705-B104-39E832A5D8BA Q38262019-770F9B61-BE4B-4BA9-9D96-0BFC747B2005 Q38521752-0EEC87BD-3D3D-4892-BE78-E4A10D9FDCB0 Q38645128-47BC732D-5486-4222-B9BD-01AAE5B795DD Q38912265-CA579A3F-D595-44CE-9F62-F14BD14D5622 Q38912327-6353702F-5D36-42B5-B51C-4E71F486A214 Q38947116-C3E2049D-4FE8-4094-8EB9-56408843ED55 Q39064497-0B7B688B-C66F-44A2-9047-D5E5B3C1A002 Q39168899-1F6C7BC8-E6FD-4FCB-9E6B-29414B75FD11 Q39678222-79FD4814-21C6-4995-B237-23048EBB057B Q42153454-7BAFE32C-8767-4B63-9BEC-B4FBA6E7CCD3 Q42259507-AA0A25CC-4C09-496C-BC07-288EDBCB138F Q42386456-F183E7BB-24AB-48C3-BA0A-59121180B26B Q43436260-D8641B53-1C78-4F22-9DC2-0ECA017823D6

P2860

Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.

http://www.wikidata.org/entity/Q34208293

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Phase IB study of gene-mediate ...... adiation for malignant glioma.

@ast

Phase IB study of gene-mediate ...... adiation for malignant glioma.

@en

Phase IB study of gene-mediate ...... adiation for malignant glioma.

@nl

type

label

Phase IB study of gene-mediate ...... adiation for malignant glioma.

@ast

Phase IB study of gene-mediate ...... adiation for malignant glioma.

@en

Phase IB study of gene-mediate ...... adiation for malignant glioma.

@nl

prefLabel

Phase IB study of gene-mediate ...... adiation for malignant glioma.

@ast

Phase IB study of gene-mediate ...... adiation for malignant glioma.

@en

Phase IB study of gene-mediate ...... adiation for malignant glioma.

@nl

P1433

Q34208293-C7937C7B-BC3C-4E7E-994A-9C9B49FBD957

P1476

Q34208293-63EB1D70-C104-4CA5-84ED-2C9C1C0FD2D6

P2093

Q34208293-048B152B-3329-4D8E-8730-20B52C4B1F1B

Q34208293-1D72412D-28C8-479A-870B-3DD13063E442

Q34208293-319ACC12-57A6-4C26-90B5-E194F2C49304

Q34208293-31E717CD-9EB7-49FC-A052-5CB23D2CAC8A

Q34208293-44F78628-DE60-4889-96DD-9512945B7B4A

Q34208293-6119B5EE-4DF1-40E6-85D3-324500EDA80D

Q34208293-6CCAA761-1129-4C3D-97B8-C214EBBE32EB

Q34208293-713B2A03-18AA-4276-BA28-46A15960145B

Q34208293-813A5D90-62D9-4E9E-AC13-6F37B49AFB9D

Q34208293-86FA063D-67D1-42EB-BE33-0C703B07D909

P2860

Q34208293-022420E9-E99B-44DE-81A9-BE1B28B487FD

Q34208293-0635B58E-23A3-44BB-8741-6A53F1353F98

Q34208293-079FCAD8-702E-4CBB-9FAC-CADA04A5FBB3

Q34208293-0B042034-FA27-4052-A91C-CFC0AE86CFEB

Q34208293-103B0AF8-C927-4ADF-A38D-90C719641C07

Q34208293-115FBE3E-DB3D-4581-AA2E-90DFB5611CF6

Q34208293-11AF389D-AAF3-42CF-8342-E5FD0F8C887C

Q34208293-13007EE0-DB33-4137-AD12-6B30E808DC7F

Q34208293-15486FBF-A538-4F46-8A8E-E214C71A8630

Q34208293-1F01900B-A727-4160-891F-9A51A6ED047A

P304

Q34208293-DCAE1962-61B2-4C5C-830D-2E83426E3B39

P31

Q34208293-86C46BAE-DC03-4686-9EF8-7979E5F257C4

P356

Q34208293-B99663A7-9A5A-49EF-AACB-64E716089E49

P407

Q34208293-6A6D6F4C-E483-47E5-802E-ABD97955D000

P433

Q34208293-0B9CEA73-DA37-4210-B866-A582077EF1D2

P478

Q34208293-ADB41AF0-D195-4D47-A45B-C78713C5296F

P577

Q34208293-D3F63BD6-D52D-405A-B2C4-E133FE489B24

P698

Q34208293-09CB2643-C8E9-495C-8230-4E4474F723D1

P921

Q34208293-847A5B86-F7AA-4935-87EE-2BAEF26E19EE

Q34208293-FD4680B0-350E-4F9C-B9C0-81956CFEEA1D

P932

Q34208293-7BEBE17C-12E8-41E4-9C27-415A8D2B6F2C

P356

JCO.2011.35.5222

P1433

Journal of Clinical Oncology

P1476

Phase IB study of gene-mediate ...... adiation for malignant glioma.

@en

P2093

Abhik Ray-Chaudhuri

http://www.w3.org/2001/XMLSchema#string

Andrea G Manzanera

http://www.w3.org/2001/XMLSchema#string

Arnab Chakravarti

http://www.w3.org/2001/XMLSchema#string

Balveen Kaur

http://www.w3.org/2001/XMLSchema#string

Carissa Monterroso

http://www.w3.org/2001/XMLSchema#string

David S Baskin

http://www.w3.org/2001/XMLSchema#string

E Antonio Chiocca

http://www.w3.org/2001/XMLSchema#string

Estuardo Aguilar-Cordova

http://www.w3.org/2001/XMLSchema#string

Herbert Newton

http://www.w3.org/2001/XMLSchema#string

Jayson Hardcastle

http://www.w3.org/2001/XMLSchema#string

P2860

The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro

HMGB1 mediates endogenous TLR2 activation and brain tumor regression

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.

Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression

Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression.

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

P304

3611-3619

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.35.5222

http://www.w3.org/2001/XMLSchema#string

P407

P433

27

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21844505

http://www.w3.org/2001/XMLSchema#string

P921

P932

3179270

http://www.w3.org/2001/XMLSchema#string